Final Program

SATURDAY • MAY 14 19
Target Audience
Researchers and public health practitioners in respiratory and environmental
health.
Objectives
At the conclusion of this session, the participant will be able to:
• understand and apply key concepts in the design and analysis of studies of
DNA methylation and lung disease;
• comprehend the impact of epigenetic studies on prevention (e.g., biomarker
development), diagnosis, and treatment of lung disease;
• learn new and alternative approaches to epigenetic studies.
Lung diseases are multi-factorial,resulting from interactions between genetic and
environmental factors. Heritable and/or de novo changes in gene expression that
occur without alterations in DNA sequence (epigenetic) mediate some environmental
effects on lung disease. We will review state of the art approaches to designing and
implementing studies of epigenetics in general and in pulmonary/critical care/sleep
medicine in particular.
Chairing: J.C. Celedon, MD, DrPH, Pittsburgh, PA
C. Breton, ScD, Los Angeles, CA
8:00 Designing Studies of DNA Methylation
J.C. Celedon, MD, DrPH, Pittsburgh, PA
8:40 Laboratory Assays for Epigenetic Studies
S. Belinsky, PhD, Albuquerque, NM
9:25 Data Analysis for Studies of DNA Methylation
C. Breton, ScD, Los Angeles, CA
10:10 Break
10:20 Murine Studies of Epigenetics
L. Kobzik, MD, Boston, MA
11:05 Birth Cohort Studies of Epigenetics
J. Herbstman, PhD, New York, NY
11:50 MicroRNA Studies
P.G. Woodruff, MD, MPH, San Francisco, CA
12:35 LUNCH
1:35 Twin Studies of Epigenetics
J.C. Celedon, MD, DrPH, Pittsburgh, PA
2:20 Break
2:30 Histone Modification
K.H. Albertine, PhD, Salt Lake City, UT
3:15 Where Do We Go from Here?
B.A. Raby, MD, MPH, Boston, MA
PG22
CLINICAL
POSTGRADUATE COURSE
CME Credits Available: 6.5
DIFFICULT CLINICAL PROBLEMS IN PULMONARY
AND CRITICAL CARE INFECTIONS
Pre-registration and additional fees required. Continental breakfast and
box lunch included. Attendance is limited.
Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300
Registrants must bring a laptop to the
course to view the course material.
Assemblies on Microbiology, Tuberculosis and Pulmonary Infections;
Clinical Problems; Critical Care
8:00 a.m. - 4:00 p.m. MOSCONE CENTER
Room 3014 (West Building, Level 3)
Target Audience
Clinicians managing patients with pulmonary and critical care acquired
infections.
Objectives
At the conclusion of this session, the participant will be able to:
• have a much greater understanding of the range of pulmonary infections
that can occur in immunocompetent and immunocompromised hosts;
• gain a much better appreciation of the evidence supporting different
treatment strategies in pulmonary infections;
• have a much better knowledge of new diagnostic tests, treatments and
outcome measures that can be applied in their local setting.
This course will provide clinicians with a broad overview and an update of the current
challenging issues in the management of pulmonary and critical care infections
including typical bacterial pneumonia, mycobacterial, fungal, and viral infections as
well as general approaches to infections in the immunocompromised host.
Chairing: C.A. Hage, MD, Indianapolis, IN
K.A. Crothers, MD, Seattle, WA
K.S. Knox, MD, Tucson, AZ
8:00 ICU Acquired CLABSI: Prevention and Management in the
Accountable Care Era
I.I. Raad, MD, Houston, TX
8:30 Emerging Viral Respiratory Tract Infections
T.E. West, MD, MPH, Seattle, WA
9:00 What Are the Big Changes in the New and Upcoming VAP/HAP
Treatment Guidelines?
M.L. Metersky, MD, Farmington, CT
9:30 Panel Discussion
M.L. Metersky, MD, Farmington, CT
I.I. Raad, MD, Houston, TX
T.E. West, MD, MPH, Seattle, WA
9:45 Break
10:00 Empyema and Other Pleural Infections
Y.C.G. Lee, MBChB, PhD, Perth, Australia
SATURDAY
ATS 2016 • San Francisco